Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Integrity Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$4,129,813

913 payments

Through program year 2025, Integrity Clinical Research LLC is reported as receiving $4,129,813 in research payments, across 913 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $56,176 3
2024 Research $356,740 7
2023 Research $628,668 193
2022 Research $1,098,386 534
2021 Research $302,518 28
2020 Research $601,782 33
2019 Research $1,085,543 115

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $1,310,850 57 payments
  2. Eli Lilly and Company $937,702 14 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $926,475 3 payments
  4. Intercept Pharmaceuticals, Inc. $318,665 70 payments
  5. Regeneron Pharmaceuticals, Inc. $286,783 679 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $203,711 4 payments
  7. Pfizer Inc. $49,061 14 payments
  8. Intercept Pharma Europe Ltd. $43,439 4 payments
  9. American Regent $35,948 5 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $8,471 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. POCC in NASH $926,475 3 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $592,300 33 payments
  3. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $531,751 5 payments
  4. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $512,594 20 payments
  5. An Adaptive Phase 2A/2B, Randomized, Double-Blind, Placebo-Controlled Study of Ly3871801 in Adult Participants With Moderately-To-Severely Active Rheumatoid Arthritis $296,860 4 payments
  6. Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) $286,783 679 payments
  7. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $176,495 1 payment
  8. A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole Opc34712 in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $132,078 1 payment
  9. An Adaptive Phase 2A/2B Randomized Double-Blind Placebo-Controlled Study of Ly3871801 in Adult Participants With Moderately-To-Severely Active Rheumatoid Arthritis $108,654 2 payments
  10. 1009742 $101,955 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record